Search Results - "Wendtner, C M"

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial by Hallek, M, Prof, Fischer, K, MD, Fingerle-Rowson, G, MD, Fink, AM, MD, Busch, R, Mayer, J, Prof, Hensel, M, Prof, Hopfinger, G, MD, Hess, G, MD, von Grünhagen, U, MD, Bergmann, M, MD, Catalano, J, MD, Zinzani, PL, Prof, Caligaris-Cappio, F, Prof, Seymour, JF, Prof, Berrebi, A, Prof, Jäger, U, Prof, Cazin, B, MD, Trneny, M, MD, Westermann, A, Wendtner, CM, Prof, Eichhorst, BF, MD, Staib, P, MD, Bühler, A, MD, Winkler, D, MD, Zenz, T, MD, Böttcher, S, MD, Ritgen, M, MD, Mendila, M, MD, Kneba, M, Prof, Döhner, H, Prof, Stilgenbauer, S, Prof

“…Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal…”
Get full text

A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients by Biehl, L.M., Huth, A., Panse, J., Krämer, C., Hentrich, M., Engelhardt, M., Schäfer-Eckart, K., Kofla, G., Kiehl, M., Wendtner, C.-M., Karthaus, M., Ullmann, A.J., Hellmich, M., Christ, H., Vehreschild, M.J.G.T.

“…Central venous catheter (CVC)-related bloodstream infections (CRBSI) are a frequent cause of morbidity and mortality in patients with chemotherapy-induced…”
Get full text

Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL by Maurer, C, Langerbeins, P, Bahlo, J, Cramer, P, Fink, A M, Pflug, N, Engelke, A, von Tresckow, J, Kovacs, G, Stilgenbauer, S, Wendtner, C-M, Müller, L, Ritgen, M, Seiler, T, Fischer, K, Hallek, M, Eichhorst, B

“…This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter’s transformations (RTs) following…”
Get full text

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) by WENDTNER, C-M, RITGEN, M, STILGENBAUER, S, DÖHNER, H, KNEBA, M, EMMERICH, B, HALLEK, M, SCHWEIGHOFER, C. D, FINGERLE-ROWSON, G, CAMPE, H, JÄGER, G, EICHHORST, B, BUSCH, R, DIEM, H, ENGERT, A

“…Patients with CLL responding to initial chemotherapy with fludarabine alone (F) or in combination with cyclophosphamide (FC) were randomized for treatment with…”
Get full text

Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature by Voth, H., Landsberg, J., Hinz, T., Wenzel, J., Bieber, T., Reinhard, G., Höller, T., Wendtner, C.-M., Schmid-Wendtner, M.-H.

“…Fibrosarcomatous transformation represents a rare event in dermatofibrosarcoma protuberans (DFSP) with unpredictable biological behaviour. No guidelines for…”
Get full text

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib by Montemurro, M, Schöffski, P, Reichardt, P, Gelderblom, H, Schütte, J, Hartmann, J.T, von Moos, R, Seddon, B, Joensuu, H, Wendtner, C.M, Weber, E, Grünwald, V, Roth, A, Leyvraz, S

“…Abstract Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intolerant to both imatinib and second-line sunitinib…”
Get full text

Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells by Kruse, U, Pallasch, C P, Bantscheff, M, Eberhard, D, Frenzel, L, Ghidelli, S, Maier, S K, Werner, T, Wendtner, C M, Drewes, G

“…The pharmacological induction of apoptosis in neoplastic B cells presents a promising therapeutic avenue for the treatment of chronic lymphocytic leukemia…”
Get full text

Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells by Pallasch, C P, Schwamb, J, Königs, S, Schulz, A, Debey, S, Kofler, D, Schultze, J L, Hallek, M, Ultsch, A, Wendtner, C-M

“…Constitutively activated pathways contribute to apoptosis resistance in chronic lymphocytic leukemia (CLL). Little is known about the metabolism of lipids and…”
Get full text

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia by Österborg, A, Foà, R, Bezares, R F, Dearden, C, Dyer, M J S, Geisler, C, Lin, T S, Montillo, M, van Oers, M H J, Wendtner, C-M, Rai, K R

“…The consensus views of an expert roundtable meeting are presented as updated management guidelines for using alemtuzumab in chronic lymphocytic leukemia. Since…”
Get full text

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells by Krause, G, Patz, M, Isaeva, P, Wigger, M, Baki, I, Vondey, V, Kerwien, S, Kuckertz, M, Brinker, R, Claasen, J, Frenzel, L P, Wendtner, C-M, Heider, K-H, Hallek, M

Get full text

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab by Fink, A M, Böttcher, S, Ritgen, M, Fischer, K, Pflug, N, Eichhorst, B, Wendtner, C-M, Winkler, D, Bühler, A, Zenz, T, Staib, P, Mayer, J, Hensel, M, Hopfinger, G, Wenger, M, Fingerle-Rowson, G, Döhner, H, Kneba, M, Stilgenbauer, S, Busch, R, Hallek, M

Get full text

Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia by Kofler, D M, Gawlik, B B, Elter, T, Gianella-Borradori, A, Wendtner, C-M, Hallek, M

Get full text

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia by Elter, T, James, R, Busch, R, Winkler, D, Ritgen, M, Böttcher, S, Kahl, C, Gassmann, W, Stauch, M, Hasan, I, Staib, P, Fischer, K, Fink, A-M, Bahlo, J, Bühler, A, Döhner, H, Wendtner, C-M, Stilgenbauer, S, Engert, A, Hallek, M

Get full text

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/‐ IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS by Cramer, P., Fürstenau, M., Giza, A., Robrecht, S., Tausch, E., Schneider, C., Wendtner, C.‐M., Hoechstetter, M., Schetelig, J., Böttcher, S., Dreger, P., Fink, A.‐M., Langerbeins, P., Al‐Sawaf, O., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.

Get full text

Risk of second primary malignancies in patients with cutaneous melanoma by Schmid-Wendtner, M-H., Baumert, J., Wendtner, C-M., Plewig, G., Volkenandt, M.

“…Background In several studies an increased risk for development of breast cancer, malignant lymphoma and neoplasms of the kidney as second primary cancers in…”
Get full text

Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials by Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., v Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Dürig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, Hallek, M., Eichhorst, B.

“…Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range…”
Get full text

Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients by Schmid-Wendtner, M.H., Brunner, B., Konz, B., Kaudewitz, P., Wendtner, C.M., Peter, R.U., Plewig, G., Volkenandt, M.

“…Between 1987 and 1998, 64 patients with lentigo maligna (LM) (n = 42) or lentigo maligna melanoma (LMM) (n = 22) were treated by fractionated radiotherapy. In…”
Get full text

Identification of native, immunogenic peptides from Cyclin D1 by von Bergwelt-Baildon, M S, Shimabukuro-Vornhagen, A, Wendtner, C M, Kondo, E

Get full text

Current status of immunotherapy in B cell malignancies by Kofler, D M, Mayr, C, Wendtner, C-M

“…Conventional treatment of hematologic malignancies mainly consists of chemotherapeutic agents or a combination of both, chemotherapy and monoclonal antibodies…”
Get more information

Advances in chemotherapy for chronic lymphocytic leukemia by Wendtner, C.-M, Eichhorst, B.F, Hallek, M.J

“…While chemotherapy based on alkylating agents has been the standard treatment of chronic lymphocytic leukemia (CLL) for decades, purine analogues and their…”
Get full text